摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(8R,8aS,6E)-8-Hydroxy-8-methyl-[(2R,4E,6S)-2,5-dimethyl-6-benzyloxymethyloxy-4-octenylidene]octahydroindolizin-7-done | 350246-39-8

中文名称
——
中文别名
——
英文名称
(8R,8aS,6E)-8-Hydroxy-8-methyl-[(2R,4E,6S)-2,5-dimethyl-6-benzyloxymethyloxy-4-octenylidene]octahydroindolizin-7-done
英文别名
(6E,8R,8aS)-6-[(E,2R,6S)-2,5-dimethyl-6-(phenylmethoxymethoxy)oct-4-enylidene]-8-hydroxy-8-methyl-2,3,5,8a-tetrahydro-1H-indolizin-7-one
(8R,8aS,6E)-8-Hydroxy-8-methyl-[(2R,4E,6S)-2,5-dimethyl-6-benzyloxymethyloxy-4-octenylidene]octahydroindolizin-7-done化学式
CAS
350246-39-8
化学式
C27H39NO4
mdl
——
分子量
441.611
InChiKey
SVUMDWHNKQDWFG-JNVXKZKZSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.4
  • 重原子数:
    32
  • 可旋转键数:
    10
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.59
  • 拓扑面积:
    59
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (8R,8aS,6E)-8-Hydroxy-8-methyl-[(2R,4E,6S)-2,5-dimethyl-6-benzyloxymethyloxy-4-octenylidene]octahydroindolizin-7-done溶剂黄146tetramethylammonium triacetoxyborohydride 作用下, 以 丙酮 为溶剂, 反应 144.0h, 以89%的产率得到(7S,8R,8aS,6E)-7,8-Dihydroxy-8-methyl-[(2R,4E,6S)-2,5-dimethyl-6-benzyloxymethyloxy-4-octenylidene]octahydroindolizidine
    参考文献:
    名称:
    (+)-别藻毒素323B'的合成
    摘要:
    本文描述了使用 (Z)-N-链烯基硝酮 4 的分子内 [3 + 2]-环加成反应合成 (+)-allopumiliotoxin 323B' (1)。该合成开始于 (R)-叔丁基- 3-羟基-pent-4-enoate [(R)-13],它是用 Amano PS 脂肪酶通过酶促拆分获得的。一系列操作得到中间体 17 并与 4-苯甲酰氧基丁醛原位偶联导致 (Z)-N-烯基硝酮 4 进行分子内 [3 + 2]-环加成反应,得到异恶唑烷 3 作为主要环加合物。异恶唑烷 3 提供哌啶酮 24,其在非对映面选择性加成 MeMgBr 后得到所需的叔醇 25。吲哚里西啶核 2 的形成是通过分子内 S(N) 2 反应实现的。侧链由正膦 8 和对映体纯醛 9 之间的 Wittig 反应组装而成。进一步的修饰得到醛 7,它与吲哚并酮核心 2 的烯醇钾发生羟醛缩合。脱水得到烯酮 37,它被转化为反二醇 38 通过分子内氢化物还原。最后,BOM
    DOI:
    10.1002/1521-3765(20010504)7:9<1845::aid-chem1845>3.0.co;2-2
  • 作为产物:
    参考文献:
    名称:
    (+)-别藻毒素323B'的合成
    摘要:
    本文描述了使用 (Z)-N-链烯基硝酮 4 的分子内 [3 + 2]-环加成反应合成 (+)-allopumiliotoxin 323B' (1)。该合成开始于 (R)-叔丁基- 3-羟基-pent-4-enoate [(R)-13],它是用 Amano PS 脂肪酶通过酶促拆分获得的。一系列操作得到中间体 17 并与 4-苯甲酰氧基丁醛原位偶联导致 (Z)-N-烯基硝酮 4 进行分子内 [3 + 2]-环加成反应,得到异恶唑烷 3 作为主要环加合物。异恶唑烷 3 提供哌啶酮 24,其在非对映面选择性加成 MeMgBr 后得到所需的叔醇 25。吲哚里西啶核 2 的形成是通过分子内 S(N) 2 反应实现的。侧链由正膦 8 和对映体纯醛 9 之间的 Wittig 反应组装而成。进一步的修饰得到醛 7,它与吲哚并酮核心 2 的烯醇钾发生羟醛缩合。脱水得到烯酮 37,它被转化为反二醇 38 通过分子内氢化物还原。最后,BOM
    DOI:
    10.1002/1521-3765(20010504)7:9<1845::aid-chem1845>3.0.co;2-2
点击查看最新优质反应信息

文献信息

  • The Synthesis of (+)-Allopumiliotoxin 323B′
    作者:Choon-Hong Tan、Andrew B. Holmes
    DOI:10.1002/1521-3765(20010504)7:9<1845::aid-chem1845>3.0.co;2-2
    日期:2001.5.4
    describes the synthesis of (+)-allopumiliotoxin 323B' (1) using the intramolecular [3 + 2]-cycloaddition reaction of the (Z)-N-alkenylnitrone 4. This synthesis began with (R)-tert-butyl-3-hydroxy-pent-4-enoate [(R)-13] which was obtained by enzymatic resolution with Amano PS lipase. A series of manipulations gave intermediate 17 and in situ coupling with 4-benzoyloxybutanal lead to the (Z)-N-alkenylnitrone
    本文描述了使用 (Z)-N-链烯基硝酮 4 的分子内 [3 + 2]-环加成反应合成 (+)-allopumiliotoxin 323B' (1)。该合成开始于 (R)-叔丁基- 3-羟基-pent-4-enoate [(R)-13],它是用 Amano PS 脂肪酶通过酶促拆分获得的。一系列操作得到中间体 17 并与 4-苯甲酰氧基丁醛原位偶联导致 (Z)-N-烯基硝酮 4 进行分子内 [3 + 2]-环加成反应,得到异恶唑烷 3 作为主要环加合物。异恶唑烷 3 提供哌啶酮 24,其在非对映面选择性加成 MeMgBr 后得到所需的叔醇 25。吲哚里西啶核 2 的形成是通过分子内 S(N) 2 反应实现的。侧链由正膦 8 和对映体纯醛 9 之间的 Wittig 反应组装而成。进一步的修饰得到醛 7,它与吲哚并酮核心 2 的烯醇钾发生羟醛缩合。脱水得到烯酮 37,它被转化为反二醇 38 通过分子内氢化物还原。最后,BOM
查看更多

同类化合物

(6E,7R,8R,8aS)-6-[(4E,6S)-6-羟基-2,5-二甲基辛-4-烯-1-亚基]-8-甲基八氢中氮茚-7,8-二醇 pumiliotoxin B pumiliotoxin B (8R,8αS)-8-hydroxy-8-methyl-6-((Z)-2(R)-methyl-hexylidene)octahydroindolizin-7-one erythro pumiliotoxin PTX-B (6Z,8S,8aS)-6-[(2R,4E,6S)-6-(benzyloxy)-2,5-dimethyl-4-octenylidene]-8-{[tert-butyl(dimethyl)silyl]oxy}-8-methyloctahydroindolizine (6Z,8S)-6-[(E,6S)-6-hydroxy-2,5-dimethyloct-4-enylidene]-8-methyl-1,2,3,5,7,8a-hexahydroindolizin-8-ol (8R,8aS,6E)-8-Hydroxy-8-methyl-[(2R,4E,6S)-2,5-dimethyl-6-benzyloxymethyloxy-4-octenylidene]octahydroindolizin-7-done (8R,8aS)-8-hydroxy-6-[(E,2R,6S)-1-hydroxy-2,5-dimethyl-6-(phenylmethoxymethoxy)oct-4-enyl]-8-methyl-1,2,3,5,6,8a-hexahydroindolizin-7-one (+)-Allopumiliotoxin 323B' Pumiliotoxin 237A (1R,2R,9aS)-1-(benzyloxy)-2-hydroxy-3(E)-isobutylidene-1-methyloctahydroquinolizine (7S,8R,8aS)-8-(benzyloxy)-7-hydroxy-8-methyl-6-(E)-<(2R)-2-methylpentylidene>octahydroindolizidine (+)-allopumiliotoxin 267 A (+)-Pumiliotoxin 251D (3E)-(5S,6S)-5-hydroxy-3-[(R)-2-methylhexylidene]-5-methylazabicyclo[4.3.0]nonan-2-one (8S,8aS)-8-hydroxy-8-methyl-6(Z)-<2(R)-methylhexylidene>octahydro-5-indolizidinone (8S,8aS)-8-hydroxy-8-methyl-(6Z)-<(2R,4E,6S)-6-(benzyloxy)-2,5-dimethyl-4-octenylidene>octahydroindolizidine (+)-(15S)-pumiliotoxin A (+)-allopumiliotoxin 339A (6E,7S,8R,8aS)-8-methyl-6-[(E,2R)-2-methyl-5-[(4R,5R)-2,2,5-trimethyl-1,3-dioxolan-4-yl]hex-4-enylidene]-8-phenylmethoxy-1,2,3,5,7,8a-hexahydroindolizin-7-ol (+)-allopumiliotoxin 339 B (7R,8R,8aS)-8-(benzyloxy)-7-hydroxy-6(Z)-<6(R),7(R)-(isopropylidenedioxy)-2(R),5-dimethyl-4(E)-octenylidene>-8-methyloctahydroindolizine (+)-homopumiliotoxin 223G (6Z)-8-methyl-6-(2-methylhexylidene)-1,2,3,5,7,8a-hexahydroindolizine-7,8-diol (7R,8R,8aS,E)-6-((2R,6R,7R,E)-6,7-Dihydroxy-2,5-dimethyloct-4-en-1-ylidene)-8-methyloctahydroindolizine-7,8-diol (8S,8aS)-6-[2,2-Dimethyl-hex-(Z)-ylidene]-8-methyl-octahydro-indolizin-8-ol (R,4E,8E)-8-((7R,8R,8aS)-7,8-Dihydroxy-8-methylhexahydroindolizin-6(5H)-ylidene)-4,7-dimethyloct-4-en-3-one (4E,7R,8Z)-8-((1S,9aS)-1-Hydroxy-1-methyltetrahydro-1H-quinolizin-3(2H,4H,6H)-ylidene)-4,7-dimethyloct-4-ene-2,3-diol (1S,9aS,Z)-3-((2R,E)-7-Hydroxy-2,5-dimethyloct-4-en-1-ylidene)-1-methyloctahydro-1H-quinolizin-1-ol (1S,9aS,Z)-3-((2R,E)-6-Hydroxy-2,5-dimethylnon-4-en-1-ylidene)-1-methyloctahydro-1H-quinolizin-1-ol (8S,8aS,Z)-6-((R,4E,6E)-2,5-Dimethylocta-4,6-dien-1-ylidene)-8-methyloctahydroindolizin-8-ol (8S,Z)-6-((2R,E)-6-Hydroxy-2,5-dimethylhept-4-en-1-ylidene)-8-methyloctahydroindolizin-8-ol (R,Z)-6-((8S,8aS)-8-Hydroxy-8-methylhexahydroindolizin-6(5H)-ylidene)-5-methylhexan-2-one (8S,8aS,Z)-6-((2R)-4-Hydroxy-2-methylpentylidene)-8-methyloctahydroindolizin-8-ol (1S,9aS,Z)-3-((S)-3-Hydroxy-2-methylpropylidene)-1-methyloctahydro-1H-quinolizin-1-ol (8S,8aS,Z)-8-Methyl-6-((R)-2-methylpentylidene)octahydroindolizin-8-ol (6E)-8-methyl-6-(2-methylhexylidene)-8-phenylmethoxy-1,2,3,5,7,8a-hexahydroindolizin-7-ol (6Z)-6-[(E)-6-hydroxy-2,5-dimethyloct-4-enylidene]-8-methyl-1,2,3,5,7,8a-hexahydroindolizin-8-ol (8S,8aS,Z)-6-((2R)-5-Hydroxy-2-methylhexylidene)-8-methyloctahydroindolizin-8-ol Allopumiliotoxin 253a (8R,8aS,E)-6-((2R,6R,E)-6-Hydroxy-2,5-dimethyloct-4-en-1-ylidene)-8-methyloctahydroindolizine-7,8-diol Pumiliotoxin 309a (6E)-8-methyl-6-(2-methylhexylidene)-1,2,3,5,7,8a-hexahydroindolizine-7,8-diol (+)-Pumiliotoxin B 8-Methyl-6-(2-methylhexylidene)-8-phenylmethoxy-1,2,3,5,7,8a-hexahydroindolizin-7-ol (1S,9aS,Z)-3-((2R)-6-Hydroxy-2,5-dimethyloctylidene)-1-methyloctahydro-1H-quinolizin-1-ol (8S,8aS,Z)-6-((R)-7-Hydroxy-2-methylheptylidene)-8-methyloctahydroindolizin-8-ol (8S,8aS,Z)-6-((R,E)-2,5-Dimethyloct-4-en-1-ylidene)-8-methyloctahydroindolizin-8-ol (8S,8aS,Z)-8-Methyl-6-((R,E)-2-methyl-5-((4R,5S)-2,2,5-trimethyl-1,3,2-dioxasilolan-4-yl)hex-4-en-1-ylidene)octahydroindolizin-8-ol